Elamipretide: Uses, Mechanism, and Side Effects

Patients and caregivers dealing with Barth syndrome often ask whether any therapy directly targets the muscle weakness this rare condition causes. Elamipretide, sold under the brand name FORZINITY, is the first drug approved for this specific use.

Key takeaways

• Elamipretide (FORZINITY) is approved to improve muscle strength in Barth syndrome patients weighing at least 30 kg.
• It works by binding mitochondrial cardiolipin and supporting inner mitochondrial membrane structure and function.
• Approval is an accelerated approval based on knee extensor strength, an intermediate endpoint, pending confirmatory data.
• At least 21 clinical trials have studied elamipretide, including work outside its approved indication.
• Reported side effects in available data are limited and include injection site reactions.

What Elamipretide Is

Elamipretide is classified as a mitochondrial cardiolipin binder. According to its label, the compound localizes to the inner mitochondrial membrane, where it helps improve mitochondrial morphology and function. This mechanism targets the cellular energy-production machinery rather than acting through a conventional receptor pathway.

What Elamipretide Is Approved For

FORZINITY is indicated to improve muscle strength in adult and pediatric patients with Barth syndrome who weigh at least 30 kg. The approval relies on accelerated approval status, grounded in demonstrated improvement in knee extensor muscle strength, which serves as an intermediate clinical endpoint. Continued approval for this use may depend on confirming clinical benefit in a follow-up trial. No boxed warning is listed on the label.

What the Evidence Shows

At least 21 clinical trials have registered elamipretide as a study compound. Beyond Barth syndrome, the drug has been investigated in other conditions. A completed Phase 2 study, ReCLAIM-2, evaluated elamipretide's safety, efficacy, and pharmacokinetics in people with non-central geographic atrophy related to age-related macular degeneration. Another completed Phase 2 trial examined four weeks of subcutaneous elamipretide for its effect on left ventricular function in patients with heart failure with preserved ejection fraction.

Reported Side Effects

Available adverse event reports for elamipretide are sparse, reflecting report counts rather than confirmed incidence or causation. The data on file include a single report each of injection site reaction and off-label use. This limited volume means broader patterns in side effects cannot be drawn from these reports alone.